TROG Cancer Research
Members Login   CQMS Login

TROG 01.02

Primary sponsor: TROG
Collaborating group: ALLG, Amgen (Neupogen)


A Phase 2 Study of Idarubicin Based Combined Modality Therapy in Primary Central Nervous System Lymphoma


This clinical research study looked at a new combination of chemotherapy drugs (Idarubicin and Methotrexate) followed by a lower dose of radiotherapy in participants with Primary Central Nervous System Lymphoma (PCNSL). The main purpose of this study was to assess the effectiveness of this treatment and its effect on the ability of patients to perform normal daily functions. In addition the acute effects of the chemotherapy was assessed.

Final accrual


Trial chairpersons

Dr Peter O’Brien, Calvary Mater Newcastle, NSW

Trial contact

Sarah Gallagher
Calvary Mater Newcastle
Phone: 02 4014 3947

Trial resources for TROG members

TROG 01,02 member page

We are thankful to our 14,500 patients who have participated in our research. Please continue the generous support.